• +1 513 549 5911 (U.S.)
  • +44 203 318 2846 (U.K.)

30 mins free consultation for each report        Upto 50% Discounts for Highest selling reports

Cystic Fibrosis Therapeutics Market

Cystic Fibrosis Therapeutics Market Forecast from 2015 till 2025


Market Synopsis:
Cystic fibrosis (CF) is a genetic disorder. Patients with CF have inherited two copies of the defective CF gene, one copy from each parent. Both parents must have at least one copy of the defective gene. CF causes severe damage to the lungs; in addition, it also affects the pancreas, liver, kidneys and intestine as well. If the CF is for long-term then the patient faces difficulty in breathing and coughing (including mucus flow) due to frequent lung infections. Other symptoms also include sinus infections, poor growth, fatty stool, clubbing of the fingers and toes, and infertility in most males. Degrees of symptoms differ from patient to patient.


Cystic fibrosis affects the cells which produce mucus, sweat and digestive juices. These secreted fluids are normally thin and slippery; but for the patients suffering from cystic fibrosis, a defective gene causes the secretions to become sticky and thick. Instead of acting as a lubricant, the secretions plug up tubes, ducts and passageways, especially in the lungs and pancreas. In the pancreas, the mucus prevents the release of digestive enzymes which allow the body to break down food and absorb vital nutrients.

Factors Influencing Market Scenario:
As per the Cystic Fibrosis Foundation Patient Registry in the United States, more than 30,000 people are living with cystic fibrosis (globally more than 70,000 patients). Approximately 1,000 new cases of CF are diagnosed each year. More than 75 % of people with CF are diagnosed by the age of 2 years. 


Rising incidences of Cystic Fibrosis is one of the important drivers for Cystic Fibrosis Therapeutics Market. Increase in geriatric population and growing awareness about the cystic fibrosis therapy will boom the market. In addition, R&D initiatives, technological advancements and improved healthcare facilities are the key factors fueling the growth of the market. Increase in government support is expected to fuel industry demand. However, introduction of generic drugs is the major restraining factor hampering the growth of cystic fibrosis therapeutics market.

 
Regional analysis:

Geographies analyzed in this research report, includes major four regions such as North America, Europe, Asia Pacific (APAC), and Latin America, Middle East & Africa (LAMEA). In the Asia Pacific region, China and India are expected to witness the fastest growing market. Some of the key driving factors in the emerging countries are large pool of patients, rising government funding, and increasing R&D investment. North America is also expected to dominate the market owing to large number of geriatric population along with high level of research and development activities which fuel the growth of the market in this region. 

Key Players: 

The global Cystic Fibrosis Therapeutics market comprises some of the key players such as AbbVie, Inc.; Allergan; AstraZeneca; F. Hoffmann-La Roche Ltd.; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Novartis International AG; Teva Pharmaceutical Industries Ltd. and Vertex Pharmaceuticals Inc.;

Recent Developments:

• In May 2018, Celtaxsys announced that it completed its Phase 2b trial assessing the safety and effectiveness of acebilustat (formerly CTX-4430) for cystic fibrosis (CF). The company is supposed to release clinical trial results in the month of July 2018.
• In May 2018, a research study conducted by a Michigan State University suggests that an antibacterial compound found in toothpaste, known as triclosan, may be part of a future cystic fibrosis (CF) treatment. The research was published in the journal Antimicrobial Agents and Chemotherapy.


• According to an observational study by researchers, after long-term treatment with Kalydeco (ivacaftor), Cystic fibrosis (CF) patients showed improved clinical outcomes and less disease progression. The research was published in the journal Thorax. Data was collected from the U.S. and U.K. cystic fibrosis registries. Researchers found that Kalydeco-treated CF patients had a significantly lower risk of death, pulmonary exacerbation, hospitalization, transplant, prevalence of CF-related complications, and pathological microorganisms, in addition to improved lung function.


• In November 2017, a clinical trial led by a pharmaceutical company, NIDDK, and additional support from other organizations found that a combination of two medications provides significant clinical benefit in a subgroup of patients with cystic fibrosis (CF).
Cystic Fibrosis Therapeutics Market Segmentation

By Drug Class: 
• Antibiotics
• Bronchodilators
• CFTR modulators
• Mucolytics
• NSAIDs
• Pancreatic enzyme supplements
• Steroids
• Others

By Route of Administration: 
• Oral drugs
• Inhaled drugs

Regions Covered:
o North America

  • U.S.
  • Canada
  • Mexico

o Europe

  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe

o Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia-Pacific 

o LAMEA

  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

									

	

Related Reports

Global Vapor Cartridge Industry Market Research Report

The Vapor Cartridge market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR of x.x% during 2018-2023. Based on the Vapor ...read more

Global Foot-And-Mouth Disease Vaccine Industry Market Research Report

The Foot-And-Mouth Disease Vaccine market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR of x.x% during 2018-2023. Bas ...read more

Global Galactosyl Transferases Industry Market Research Report

The Galactosyl Transferases market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR of x.x% during 2018-2023. Based on th ...read more

Global Hemorrhoids Drug Industry Market Research Report

The Hemorrhoids Drug market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR of x.x% during 2018-2023. Based on the Hemor ...read more

Global Meningococcal Polysaccharide Vaccine(Group A/C/Y/W135) Industry Market Research Report

The Meningococcal Polysaccharide Vaccine(Group A/C/Y/W135) market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR of x.x ...read more

Choose License Type

Single User - This is a single user license, allowing one specific user access to the product.

Multi User - This is a 1-5 user licence, allowing up to five users have access to the product.

Enterprise User - This is an enterprise license, allowing all employees within your organisation access to the product. The report will be emailed to you.

Why Choose Us

  • Lowest Price Guarantee
  • We offer the lowest prices for the listed reports
  • Data Security
  • Your data is safe and secure
  • Vast Report Database
  • We have more than 2 Million reports in our database
  • Client Focused
  • Personalized updates and 24*7 support
  • Trusted Source and Quality
  • We only work with reputable partners providing high quality research and support
  • Market Segmentation
  • We provide alternative views of the market to help you identify where the real opportunities lie
  • Bulk Discounts
  • We offer great discounts on purchase of multiple reports

How To Reach Us

Reach out to our most senior Sales Professional- Jay Matthews
   +1 513 549 5911 (US)
          +44 203 318 2846 (UK)
   sales@reportsmonitor.com

Our Clients

Testimonials

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed.
-VP of a Automotive division in Germany

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements
-Product Manager at US based Manufacturer

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process
--Marketing Manager at a pharma company in Belgium

Enquire Before Buying

Need to ask a quick question before buying? Please fill out this short form:

Our Features

Wide Network of Publishers

Wide Network of Publishers

Access to over 1M+ market research reports

Trusted by the Best

Trusted by the Best

50+ Clients in Fortune 500

Competitive Pricing

Competitive Pricing

Our regular promotional offers and discounts make us the most economic seller of market reports

Safe and Secure

Safe and Secure

Your payment details are protected by us.